Upon visiting a member of the CLL treatment team, you may be asked to donate blood for use in the CLL Experimental Therapeutics Laboratory. The donation is completely voluntary and a decision not to participate does not affect the world class care you receive at The James Cancer Hospital. Below are listed two studies in which blood donations are used. Also see links to the consent forms for these studies. We encourage patients to read the consent forms before their visits so that they can ask questions. If you do have any questions about donating blood to translational research efforts in the CLL Experimental Therapeutic Research Laboratory, please contact Amber Gordon via phone (614-292-8675) or email (Amber.Gordon@osumc.edu)
The purpose of this protocol is to collect blood and tissue (bone marrow, lymph node biopsies, and skin biopsies) from patients with chronic lymphocytic leukemia/small lymphoma (CLL/SLL). Assessments will be used for clinical and translational research investigating the molecular basis of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and their clinical manifestations. New technologies now permit the simultaneous characterization of pathogenic events ranging from the control of gene expression to the characterization of the molecular events of cell-cell interactions. Applying these methods to CLL/SLL in the context of a natural history protocol can help unravel cellular pathways involved in pathogenesis and disease progression and lead to the discovery or the validation of therapeutic targets. CLL/SLL is an incurable disease for which there are no cell lines and only a few mouse models. There is an urgent need to obtain a flow of primary samples to advance research into pathogenesis and novel treatment approaches.
The goals of this project are to achieve an understanding of the biologic and genetic basis for chronic lymphocytic leukemia (CLL) and to define curative treatment strategies for this disease. To achieve these goals, we have established a multi- institutional research enterprise, designated the “CLL Research Consortium” (CRC). The CRC coordinates and facilitates basic and clinical research on the genetic, biochemical, and immunologic basis of CLL. The CRC will also study families that have multiple members afflicted with CLL to identify environmental risk factors and genetic factors that might predispose to developing CLL. The CRC has established a multi-institutional CLL Clinical Consortium to enable uniform, high-volume sample accrual and inter- institutional phase I/II clinical studies. This allows the CRC to research novel biologic and pharmacologic treatments for CLL, and to examine for clinical laboratory relationships that ultimately may permit improved clinical staging and/or assist in the evaluation of the response to novel therapies. Members of CLL Research Consortium include The Ohio State University, MD Anderson Cancer Center, Dana Farber Cancer Institute, Mayo Clinic, Long Island Jewish Hospital and University of California San Diego. Finally, the CRC has a Clinical Advisory Committee that can advise established cooperative groups on the relative merits of novel treatment strategies being considered for phase III testing.